Neuroendocrine tumours of the lung

Symposium
Chairs: E. Quoix (Strasbourg, France), G. Friedel (Gerlingen, Germany)
Aims: The aims of the symposium are to outline the changes introduced by the new WHO pathological classification in the spectrum of neuroendocrine tumours of the lung, the specific management that should be applied to the aggressive large cell neuroendocrine tumour, and to discuss the best therapeutic approach to the relatively benign carcinoid tumour and, in contrast, the highly malignant small cell lung cancer.

Balanced indications for surgery or endobronchial therapy for typical carcinoid tumours G. Massard (Strasbourg, France)
Should there be a specific management for large cell neuroendocrine carcinoma? G. Rossi (Modena, Italy)
Respective indications of chemotherapy, radiotherapy and surgery in limited disease stage small cell lung carcinoma P. E. Postmus (Amsterdam, The Netherlands)